Jefferies, Goldman Decode MDR Impact on UPI Payments for Paytm, Pine Labs

UPI MDR Implementation: A Game Changer for Paytm and Pine Labs

The introduction of a Merchant Discount Rate (MDR) on UPI transactions is poised to significantly reshape the revenue landscape for digital payment players like Paytm and Pine Labs.

Understanding the MDR Structure

The MDR framework introduces a distribution model that allocates the 40 basis points (bps) across various stakeholders in the payment ecosystem. According to Emkay Global, the breakdown is as follows: issuing banks will receive 16 bps, acquiring banks will take 12 bps, Payer Third Party Application Providers (TPAP) will get 8 bps, and Payer Payment Service Provider (PSP) banks will retain 4 bps. This structure indicates that while issuing banks capture the majority of the MDR, companies like Paytm and Pine Labs, as acquirers, will benefit from their share of the 12 bps allocated to acquiring banks.

Paytm’s Earnings Potential

Jefferies has highlighted that the MDR on UPI transactions could lead to significant earnings growth for Paytm. The brokerage has revised its earnings estimates for FY28-29 upwards by 10-12%, reflecting the anticipated revenue boost from the new MDR structure. Additionally, Jefferies has raised its FY27 profit forecast by 18%, indicating a positive outlook for the company as it adjusts for exemptions and competitive pricing dynamics.

Goldman Sachs also sees the potential for substantial earnings upgrades for Paytm, estimating an incremental EBITDA of around ₹14 billion in FY28 under a high-end scenario. This figure could represent 43-70% of its current EBITDA estimate for that fiscal year. However, the brokerage cautions that competitive pressures may limit how much of the MDR can be passed on to merchants, which could affect overall profitability.

Pine Labs’ Strategic Positioning

Pine Labs is also well-positioned to capitalize on the MDR changes. Jefferies estimates that the new MDR framework could generate an additional revenue opportunity of ₹1.6 billion by FY28, which would account for approximately 20% of the company’s estimated EBITDA and profit after tax (PAT) for that year. The brokerage has maintained a ‘Buy’ rating on Pine Labs, increasing its target price from ₹180 to ₹235.

Emkay Global echoes this sentiment, projecting a conservative estimate of ₹1.55 billion in UPI MDR revenue for Pine Labs by FY28, based on a 6 bps realized take-rate. This positive outlook has led Emkay to retain its ‘Buy’ rating and raise the target price to ₹230.

Key Takeaways for Investors

• Paytm and Pine Labs are set to benefit from the introduction of a 0.4% MDR on UPI transactions above ₹2,000.
• Jefferies has raised its earnings estimates for Paytm, indicating a potential upside in profitability.
• Goldman Sachs anticipates significant EBITDA growth for Paytm, although competitive pressures may impact margin expansion.
• Pine Labs could see a substantial revenue boost from the MDR, with Jefferies projecting an additional ₹1.6 billion by FY28.
• Both brokerages maintain ‘Buy’ ratings on Paytm and Pine Labs, reflecting strong market confidence.

Investor Note: The introduction of MDR on UPI transactions marks a pivotal moment for digital payment players, with Paytm and Pine Labs positioned to leverage this change for substantial revenue growth. Investors should monitor the evolving competitive landscape and the impact of MDR on profitability as these companies adapt to the new framework.